Ratings Cutia Therapeutics

Equities

2487

KYG2606C1006

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 am EDT			5-day change	1st Jan Change
6.6 ^HKD	+1.23%		-8.33%	-39.89%

May. 31	Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	MT
May. 30	Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
CUTIA THERAPEUTICS	-39.89%	254M	-
ELI LILLY AND COMPANY	+45.82%	754B	C+
NOVO NORDISK A/S	+40.95%	630B	B
JOHNSON & JOHNSON	-6.16%	352B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	298B	C+
ASTRAZENECA PLC	+18.45%	250B	B+
NOVARTIS AG	+11.88%	217B	B-
ROCHE HOLDING AG	-0.78%	216B	A+
AMGEN INC.	+5.90%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes